Advertisement

Search Results

Advertisement



Your search for ,MbA matches 853 pages

Showing 501 - 550


breast cancer

Renowned Breast Cancer Researcher, Angela Hartley Brodie, PhD, Dies at 82

Angela Hartley Brodie, PhD, Professor Emeritus in the Department of Pharmacology at the University of Maryland School of Medicine, and an internationally recognized scientist whose groundbreaking cancer research is considered among the greatest advances in treating breast cancer, passed away on...

CancerCare Releases Research on Patient Values Initiative

MANY FACTORS can influence treatment decisions patients make concerning their cancer care. These include safety, efficacy, and cost, among other concerns. Recently, CancerCare, a national organization dedicated to providing assistance at no cost to anyone affected by cancer, established the...

issues in oncology

CancerCare Establishes Patient Values Initiative, Releases Focus Group Assessment

CancerCare has announced the establishment of the CancerCare Patient Values Initiative, a multipronged effort with an aim to reframe the national health-care policy dialogue so that it includes what is important to patients and their families. As the first step of this important project,...

breast cancer

ASCO 2017: I-SPY 2 Trial: Combination of Pembrolizumab Plus Standard Neoadjuvant Therapy in High-Risk Breast Cancer

At the 2017 ASCO Annual Meeting, results were presented from the phase II I-SPY 2 trial investigating pembrolizumab (Keytruda) in combination with standard therapy (paclitaxel followed by doxorubicin and cyclophosphamide) as a neoadjuvant treatment for patients with locally advanced triple-negative ...

lymphoma

Julie Vose, MD, MBA, on DLBCL and FL: Expert Commentary on Two Studies

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses two hematologic abstracts: results from the OPTIMAL>60 study on radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly patients with diffuse large B-cell lymphoma; and an analysis of autologous...

Clifford A. Hudis, MD, and Julie Vose, MD, MBA: A Conversation With ASCO’s CEO

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Clifford A. Hudis, MD, ASCO’s current CEO, discuss the state of cancer care and the challenges that lie ahead.

Bruce E. Johnson, MD, and Julie Vose, MD, MBA: A Conversation With ASCO’s 2017–2018 President

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Bruce E. Johnson, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discuss Dr. Johnson’s upcoming tenure as ASCO President and his goals for the year ahead.

ASCO Presidents Through the Years

2016–2017 Daniel Hayes, MD 2015–2016 Julie Vose, MD, MBA 2014–2015 Peter Paul Yu, MD, FACP 2013–2014 Clifford A. Hudis, MD, FACP 2012–2013 Sandra M. Swain, MD 2011–2012 Michael P. Link, MD 2010–2011 George W. Sledge, Jr, MD 2009–2010 Douglas W. Blayney, MD 2008–2009 Richard...

Pharmaceutical Companies Collaborate in NCCN Oncology Research Program

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has funded three studies in its first multi-­industry collaborative research project, in which Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company are collaborating with NCCN to study combination...

My Year of Living Wonderfully: 12 Months as ASCO President

EACH YEAR, the ASCO President chooses a theme for his or her term, which is not a trivial pursuit. Trying to think up something novel and catchy, yet not schmaltzy, is quite a challenge. However, in my year as Chair of the Scientific Program Committee for the 2010 ASCO Annual Meeting, then during...

bladder cancer

AUA 2017: Studies Examine Bladder Cancer Risk and Mortality in E-Cigarette and Traditional Smokers

Data presented at the 2017 Annual Scientific Meeting of the American Urological Association (AUA) showed harmful links between the use of e-cigarettes and bladder cancer risk, and associated the smoking of traditional cigarettes to a higher risk of mortality among patients with bladder cancer. Even ...

Ahmad Samer Al-Homsi, MD, MBA, to Lead New Bone Marrow Transplantation Initiative at NYU

Hematologist-oncologist Ahmad Samer Al-Homsi, MD, MBA, will lead a new bone marrow transplantation program at New York University (NYU) Langone’s Perlmutter Cancer Center for treating blood-borne cancers and potentially utilize transplantation as an adjunct to immunotherapy for solid tumors. He...

ASCO Selects 2017–2018 Health Policy Fellows

ASCO has announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017–2018 ASCO Health Policy Fellowship program, now entering its 2nd year. The fellowship provides early-career oncologists the skills they need to monitor and shape the regulatory and legislative ...

Cancer Research UK Awards Six U.S. Scientists $87 Million as Part of ‘Grand Challenge’

Cancer Research UK has announced that six leading American scientists are among the winners of a global competition to help overcome the biggest challenges facing cancer research. The initial $87 million “Grand Challenge” fund will be distributed across 4 international teams of academics from 6...

prostate cancer

ASCO Provisional Clinical Opinion: Second-Line Hormonal Therapy for Chemotherapy-Naive Castration-Resistant Prostate Cancer

As reported by Katherine S. Virgo, PhD, MBA, of Emory University, and colleagues in the Journal of Clinical Oncology, ASCO has issued a provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer. The provisional clinical opinion applies...

solid tumors

Selected Clinical Trials of CDK4/6 Inhibitors

This Clinical Trials Resource Guide includes a selection of actively recruiting clinical trials of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib in multiple tumor types. All of the studies here and many others are listed on the National...

NCCN Foundation Board of Directors Names New Leadership

The NCCN Foundation® has named Gena Cook, Cofounder and Chief Executive Officer of Navigating Cancer, as Chair of the National Comprehensive Cancer Network® (NCCN®) Foundation Board of Directors. Ms. Cook, who was elected to the Board in 2010, succeeds  Ellen O. Tauscher, former U.S....

ASCO Selects 2017–2018 Health Policy Fellows

ASCO has announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017–2018 ASCO Health Policy Fellowship program, now entering its second year. The fellowship, aimed at early career oncologists, provides the skills necessary to monitor and shape the regulatory and ...

ASCO Honors Researchers, Scientists for Significant Advances in Cancer Treatment and Care

ASCO and the Conquer Cancer Foundation (CCF) proudly announce the winners of ASCO’s Special Awards, the Society’s highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked ...

Mark S. Soberman, MD, MBA, FACS, Named ACCC President

Mark S. Soberman, MD, MBA, FACS, was elected as the 2017–2018 President of the Association of Community Cancer Centers (ACCC) during its 43rd Annual Meeting on March 31, 2017, in Washington, DC. Dr. Soberman brings a wealth of experience in thoracic surgery, thoracic oncology, and value-based...

cns cancers

Study Finds Vaccine-Chemotherapy Combination Prolongs Overall Survival in Glioblastoma

Despite highly aggressive therapy that includes maximal tumor resection, high-dose radiation, and temozolomide chemotherapy, the prognosis for patients with newly diagnosed glioblastoma is dismal, with a median survival of less than 15 months, prompting researchers to study novel approaches to...

Forging a New Role to Make Curing More Cancers a Reality

For more than 3 decades, Nancy E. Davidson, MD, has dedicated her clinical and research career to better understanding the molecular mechanisms driving the development of breast cancer and to the discovery of more effective therapies to treat the disease. The recipient of an ASCO Young...

Fred Hutchinson’s Paulovich Laboratory to Lead Protein Assay Work for National Cancer Moonshot

The Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, which represents a partnership among the National Cancer Institute (NCI), the Department of Defense, and the Department of Veterans Affairs, has tapped the Paulovich Laboratory at Fred Hutchinson Cancer Research...

Lauren Lawrence, MBA, RHIA, Appointed Vice President of Karmanos Cancer Network

Lauren Lawrence, MBA, RHIA, has been promoted to Vice President of Karmanos Cancer Network. She will report to Justin Klamerus, MD, MMM, President of Karmanos Cancer Hospital and Karmanos Cancer Network. Ms. Lawrence most recently served as Executive Director of Community-Based Programs at the...

JOP Publishes Clinical Pathways and Patient Safety Studies From Quality Care Symposium

The Journal of Oncology Practice (JOP) published three articles online in conjunction with the oral presentations of the data during ASCO’s 2017 Quality Care Symposium in Orlando. “The research presented at ASCO’s Quality Care Symposium enhances our understanding of a wide variety of methods to...

An Evening for Cancer Survivors and Caregivers: Bringing Together a Community of Support

On January 26, 2017—prior to the official opening of the 2nd Annual Cancer Survivorship Symposium—cancer survivors, caregivers, patient advocates, family physicians, oncology providers, and others gathered in San Diego, California, to make connections, discuss survivorship issues, and get expert...

ASCO Launches Its New Journal Dedicated to Informatics

On February 23, 2017, ASCO launched its newest online-only journal, JCO Clinical Cancer Informatics (JCO CCI). The first four articles published in JCO CCI are: 1) An editorial from JCO CCI Editor-in-Chief Debra A. Patt, MD, MPH, MBA, introducing the publication and laying out its objective of...

Major Pharmaceutical Companies Collaborate in NCCN Research Project

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has funded three studies in its first multi-industry collaborative research project in which Boehringer Ingelheim and Eli Lilly are collaborating with NCCN to study combination therapeutic agents in ...

health-care policy
pain management

ASCO Addresses New Policies That Threaten Access to Opioids

Since the mid-2000s, medication and illicit drug abuse in the United Sates has steadily increased, creating what has now been termed an “opioid epidemic.” In response, Congress and the Bush and Obama Administrations have launched intervention and regulatory proposals to help turn the troubling...

lung cancer

Shraddha M. Dalwadi, MBA, on Stage I NSCLC: Racial Disparities in Treatment and Outcome

Shraddha M. Dalwadi, MBA, MD Candidate in the class of 2017 at Texas A&M Health Science Center, discusses findings from a SEER database study that showed African Americans and American Indians with stage I non–small cell lung cancer were less likely to receive definitive treatment and had lower ...

ASCO Honors Researchers and Scientists for Significant Advancements in Cancer Treatment and Care

ASCO and the Conquer Cancer Foundation of ASCO (CCF) have proudly announced the winners of ASCO's Special Awards, the Society's highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders...

cost of care

Financial Stress in Patients With Locally Advanced Head and Neck Cancer

In a single-institution study reported in the Journal of Oncology Practice, de Souza et al found that two-thirds of patients with locally advanced head and neck cancer had to use a financial coping strategy to help pay for care within the first 6 months of treatment. Study Details The study...

issues in oncology

John V. Cox, DO, MBA, on 2017 Quality Care Symposium Highlights: Expert Perspective

John V. Cox, DO, MBA, of the Parkland Health System/UTSW, discusses some of the key presentations at the 2017 Quality Care Symposium (Abstracts 3, 37, 52).

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of cancers...

global cancer care

Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bangladesh

The ASCO Post is pleased to present this special focus on the worldwide cancer burden. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For the convenience of the reader, each issue will focus on one country from one of the six regions...

From Azerbaijan to America: An IDEA Recipient’s Experience

Cancer takes away millions of lives every year, and in low- and middle-income countries, the high cancer mortality rate can often be attributed to scarce means and a shortage of trained professionals. Hoping to contribute my best in the fight against this disease, I chose to become an oncologist in ...

ASCO Participates in Final White House Moonshot Event

On January 11, representatives from ASCO participated in the final event in the Cancer MoonshotSM “Making Health Care Better” series, which focused on community oncology, at the White House. ASCO community members attending the event, titled “Addressing the Cancer Challenge: Progress in Research,...

Growing Leadership Development Program Tasks Participants With Increasing Society Engagement

The 2016–2017 ASCO Leadership Development Program recently welcomed 16 new participants to its ranks. The Leadership Development Program is a yearlong program designed to shape future leaders by teaching them valuable leadership skills and providing them with networking and mentorship opportunities ...

cost of care

The Cost of a Patient’s Last Ride

It was a call from a referring physician who wanted the patient to be transferred to our major academic center. The patient had a history of a lethal malignancy in a very advanced stage. The patient was already outside the bell curve, for she had survived far longer than expected for a malignancy...

thyroid cancer
survivorship

Dong Wook Shin, MD, DrPH, MBA, on Thyroid Cancer: Risk of Side Effects

Dong Wook Shin, MD, DrPH, MBA, of Seoul National University Cancer Hospital, discusses the risk of coronary heart disease and ischemic stroke in patients with thyroid cancer taking levothyroxine (Abstract 105).

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of...

health-care policy

How ASCO’s New Health Policy Fellowship Program Is Helping Shape Future Cancer Care Policy

In October 2015, ASCO launched the Health Policy Fellowship program to help the next generation of oncologists with an interest in health policy to develop the skills and experience necessary to achieve their goals and shape cancer care policy in an increasingly complicated and diverse care...

ASCO Launches JCO Clinical Cancer Informatics

JCO Clinical Care Informatics (JCO CCI) will be the first ASCO journal devoted to applications of biomedical informatics to cancer care. Debra Patt, MD, MPH, MBA, the Editor-in-Chief of JCO CCI, understands how important biomedical informatics research is to the oncology field. Dr. Patt coauthored ...

Monica M. Bertagnolli, MD, Elected ASCO President for 2018–2019 Term

Monica M. Bertagnolli, MD, a long-time member and volunteer, has been elected to serve as President of ASCO for the term beginning in June 2018. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2017. Additionally, three new members were elected to the ASCO...

gastroesophageal cancer

Geoffrey Ku, MD, MBA, on Gastric and Esophageal Cancers: Expert Perspectives on Immunotherapy

Geoffrey Ku, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses the promise of immunotherapy drugs and the search for biomarkers that will help identify patients more likely to respond, not only to these medications, but to combinations of immunotherapies, other targeted treatments,...

Gilberto de Lima Lopes, Jr, MD, MBA, FAMS, Named New Editor-in-Chief of ASCO’s Journal of Global Oncology

ASCO announced that Gilberto de Lima Lopes, Jr, MD, MBA, FAMS, will become Editor-in-Chief of the Society’s Journal of Global Oncology (JGO) in early 2017. Dr. Lopes will direct the editorial scope of JGO, an online-only, open-access journal addressing the unique challenges of cancer care and...

American Cancer Society Welcomes Three New Members and Newly Elected Officers to Board of Directors

The American Cancer Society announced the election of three new members—Amit Kumar, PhD, Joseph M. Naylor, and William D. Novelli—to the 2017 American Cancer Society Board of Directors. In addition, the new key officer leadership positions were announced, which include Arnold M. Baskies,...

Women in Oncology: Breaking Down Barriers and Looking to the Future

There has been no better time than the present for women in the field of oncology: Women at all stages of their careers are finding more opportunities and avenues to excel. At the time of the last ASCO workforce survey, women made up 28.4% of the oncologist workforce, and that proportion is rising...

Matt Ewend, MD, FACS, Named President of the University of North Carolina Physicians

Matt Ewend, MD, FACS, has been named President of the University of North Carolina (UNC) Physicians. In this role, Dr. Ewend will oversee the physician clinical enterprise of UNC Health Care, which includes more than 2,400 physicians and 600 advanced practice providers in 450 practices spanning...

University of Hawaii Cancer Center Receives $3 Million R01 NCI Grant for Bladder Cancer Research

Charles Rosser, MD, MBA, FACS, Professor and Director of the Clinical Trials Office and Director of the Clinical and Translational Research Program at the University of Hawaii Cancer Center, received a 5-year National Cancer Institute (NCI) R01 grant worth more than $3 million. The grant is for...

Advertisement

Advertisement




Advertisement